and humans, resulting in relatively mild changes in the microtubule structure of cancer cells. In 2018, Dr. Nilambra Dogra et al. studied the effects of fenbendazole (FZ) on a NSCLC (non-small-cell lung cancer) cell line in vitro and in vivo mouse xenografts and make this favorable conclu...
“We hope that our research will bring attention to often overlooked methods for treating cancer as well as managing the symptoms from conventional treatment,” said Paul E. Marik, M.D., FCCM, FCCP, lead author of the study, chief scientific officer of the FLCCC and former Chief...
Drugs that are already clinically approved or experimentally tested for conditions other than cancer, but are found to possess previously unrecognized cytotoxicity towards malignant cells, may serve as fitting anti-cancer candidates. Methyl N-(6-phenylsulfanyl-1H benzimidazol-2-yl) carbamate [Fenbendazol...
Fenbendazole is generally considered to have low toxicity to humans and animals when used as directed. However, high doses may cause mild gastrointestinal side effects such as nausea, vomiting, or diarrhea. It has not been classified as a carcinogen, but prolonged exposure or misuse may cause he...